Navigation Links
SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
Date:8/6/2008

Leading Non-Fusion Spine Surgeon Supports Company's Goals for Global

Medical Research, Education

SAN DIEGO, Aug. 6 /PRNewswire/ -- SpineMark Corporation, a spine care services organization that partners with hospitals and physicians to develop spine centers, research organizations and medical education training centers, has appointed Dr. Rudolf Bertagnoli, chairman and founder of ProSpine (Bogen, Germany), as chairman of its International Medical Advisory Board. In this role, Bertagnoli will oversee the recruitment of a global panel of physician advisors to manage the development of spine centers of excellence and clinical trials being conducted outside the United States to evaluate new technologies and treatment options for spinal disorders and injuries.

"Dr. Bertagnoli is an active leader in global spinal research studies with more than 20 years of experience pioneering fusion and non-fusion technologies for treatment of spinal disorders," said Marcy T. Rogers, M.Ed., president and CEO of SpineMark. "We believe in bringing together the best spine physicians from around the world to help us build international bridges for education, facility development and clinical research. Dr. Bertagnoli's experience is a great fit to help us achieve our goals of providing advanced spine treatment options to patients on a global level."

Bertagnoli is the founder, CMO and CEO of ProSpine, the first European Centre for Spine Arthroplasty and Associated Non-Fusion Technologies, which has five facilities across Germany. Bertagnoli has been published in key medical journals worldwide, and has trained over 3,000 surgeons from 50 countries in new minimally invasive spine techniques. Additionally, he is the founder and former president of the Spine Arthroplasty Society (SAS), president of Spine Evolution Nucleus Europe (SEN), a member of the North American Spine Society (NASS), a faculty member of IMAST and a past German representati
'/>"/>

SOURCE SpineMark Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
2. SAFC Appoints New Vice President of Quality and Regulatory Affairs
3. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
4. ARCA biopharma Appoints James Carr as Vice President of Marketing
5. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
6. Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales
7. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
8. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
9. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
10. AMT Appoints Director Global Marketing and Sales
11. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia 2HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia 3New technology could boost disease detection tests' speed and sensitivity 2Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6